http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2566205-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fae54a7443e34743f13c2eccb2156e34 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-48 |
| filingDate | 2013-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa42600a17a2fbe1bca5303f1a4f3e89 |
| publicationDate | 2016-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2566205-T3 |
| titleOfInvention | TYK2 kinase inhibitors |
| abstract | A compound that is an amide of the formula (2): ** Formula ** or a salt or stereoisomer thereof; where: R7 is selected from chlorine and fluorine; R3, R4, R5 and R6 are each independently selected from hydrogen, fluorine and chlorine; n is 0, 1 or 2; Q1 is selected from C (> = O), S (> = O) and SO2; A is absent or is NR2; R1 is selected from: hydrogen; - a C1-3 alkyl group optionally substituted with one or more substituents selected from hydroxy, amino and methylamino; and - 5-6 membered heterocyclic rings selected from pyrrolidine and piperidine, the heterocyclic rings being optionally substituted with a methyl group; R2, when present, is selected from hydrogen and methyl; or NR1R2 forms a 5- to 6-membered heterocyclic ring selected from pyrrolidine and morpholine, the heterocyclic ring being optionally substituted with a hydroxymethyl group; with the proviso that: (i) no more than two of R3 to R6 are different from hydrogen; and (ii) when R7 and R6 are both fluorine, then one of R3 to R5 is chlorine or fluorine and / or R1-A-Q1 is selected from ethylsulfonyl and isopropylsulfonyl. |
| priorityDate | 2012-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.